Hyperglycemia-induced proliferation of adult human beta cells engrafted into spontaneously diabetic immunodeficient NOD-Rag1null IL2rγnull Ins2Akita mice.

1Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 2Department of Pathology, University of Florida, Gainesville, FL 3Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 4The Jackson Laboratory, Bar Harbor, ME.
Pancreas (Impact Factor: 3.01). 10/2011; 40(7):1147-9. DOI: 10.1097/MPA.0b013e31821ffabe
Source: PubMed
  • [Show abstract] [Hide abstract]
    ABSTRACT: Therapies that increase functional β-cell mass may be the best long-term treatment for diabetes. Significant resources are devoted toward this goal, and progress is occurring at a rapid pace. Here, we summarize recent advances relevant to human β-cell regeneration. New β-cells arise from proliferation of pre-existing β-cells or transdifferentiation from other cell types. In addition, dedifferentiated β-cells may populate islets in diabetes, possibly representing a pool of cells that could redifferentiate into functional β-cells. Advances in finding strategies to drive β-cell proliferation include new insight into proproliferative factors, both circulating and local, and elements intrinsic to the β-cell, such as cell cycle machinery and regulation of gene expression through epigenetic modification and noncoding RNAs. Controversy continues in the arena of generation of β-cells by transdifferentiation from exocrine, ductal, and alpha cells, with studies producing both supporting and opposing data. Progress has been made in redifferentiation of β-cells that have lost expression of β-cell markers. Although significant progress has been made, and promising avenues exist, more work is needed to achieve the goal of β-cell regeneration as a treatment for diabetes.
    Current opinion in endocrinology, diabetes, and obesity 04/2014; 21(2):102-8. DOI:10.1097/MED.0000000000000042 · 3.77 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: γ-aminobutyric acid (GABA) exerts protective and regenerative effects on mouse islet β-cells. However, in humans it is unknown whether it can increase β-cell mass and improve glucose homeostasis. To address this question, we transplanted a suboptimal mass of human islets into immunodeficient NOD-scid-gamma mice with streptozotocin-induced diabetes. GABA treatment increased grafted β-cell proliferation, while decreasing apoptosis, leading to enhanced β-cell mass. This was associated with increased circulating human insulin and reduced glucagon levels. Importantly, GABA administration lowered blood glucose levels and improved glucose excursion rates. We investigated GABA receptor expression and signaling mechanisms. In human islets, GABA activated a calcium-dependent signaling pathway through both GABAAR and GABABR. This activated the PI3K-Akt and CREB-IRS-2 signaling pathways that convey GABA signals responsible for β-cell proliferation and survival. Our findings suggest that GABA regulates human β-cell mass and may be beneficial for the treatment of diabetes or improvement of islet transplantation.
    Diabetes 07/2014; 63(12). DOI:10.2337/db14-0153 · 8.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cure of type 1 diabetes (T1D) by immune intervention at disease onset depends on the restoration of insulin secretion by endogenous beta cells. However, little is known about the potential of beta cell mass and function to recover after autoimmune attack ablation. Utilizing a longitudinal in vivo imaging approach we here show how functional status and mass of beta cells adapt in response to onset and remission of T1D. We demonstrate that infiltration reduces beta cell mass prior to diabetes and, together with emerging hyperglycemia, affects beta cell function. After immune intervention persisting hyperglycemia prevents functional recovery, but promotes beta cell mass increase in mouse islets. When blood glucose levels return to normoglycemia beta cell mass expansion stops and subsequently glucose tolerance recovers in combination with beta cell function. Similar to mouse, human islets exhibit cell exhaustion and recovery in response to transient hyperglycemia. However, the effect of hyperglycemia on human islet mass increase is minor and transient. Our data demonstrate a major role of functional exhaustion and recovery of beta cells during diabetes onset and remission. Therefore, these findings support early intervention therapy of diabetes. © 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
    Diabetes 01/2015; DOI:10.2337/db14-1055 · 8.47 Impact Factor

Full-text (2 Sources)

Available from
May 26, 2014